A Phase 3 interventional study of telmisartan+amlodipine fixed dose combination in Hypertension, sponsored by Boehringer Ingelheim. Completed at 1 site in China. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2014-06-27.
Sponsored by Boehringer Ingelheim · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 99 studies testing telmisartan in Hypertension — 1 open to participants now, 1 under way, none of them phase 3. Telmisartan · Hypertension.
Among the 99 studies testing telmisartan in Hypertension, this one is the 91st largest by enrollment, is one of 6 that started in 2010, is one of 40 in phase 3, and was the 42nd registered.
6,128 studies on the registry are indexed under Hypertension; 911 are open to participants now.
Browse Hypertension studies →1 of the 99 studies testing telmisartan in Hypertension is open now, in 1 country. Recruiting first, the newest first:
Chong Kun Dang Pharmaceutical · Sites in Korea, Republic of
Ages 19–75
By country, each count listing its studies:
Telmisartan: first FDA approval 1998 (MICARDIS), first EMA approval 1998. What it is approved for, and how studies give it, is on its page →
Of the 556 Hypertension studies recruiting now, 262 (47%) set no upper age limit and 198 (36%) stop at 75 or younger; 40 take children under 18; 137 take healthy volunteers.
This study: 18 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
99 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 16 · Phase 2 5 · Phase 3 40 · Phase 4 32
First in 1997; this study’s year is marked. 6 started in 2010.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 27 is below the median of 100 across 4,585 interventional studies indexed under Hypertension.
Median enrollment 184 across the 99 interventional studies. Of the 91 that completed or were terminated, 14 (15%) have results posted.
This tab as a report to print or save as PDF → With an account.
75 of 99 have an industry lead sponsor. The 10 most frequent:
Boehringer Ingelheim is the lead sponsor of 2,305 studies on the registry; 62 are open to participants now.
Of its 169 completed or terminated interventional studies of FDA-regulated products, 123 (73%) have results posted.
122 studies in Hypertension by Boehringer Ingelheim: 1 open now, 1 under way, 1 of them phase 3. Of 120 finished, 41 (34%) have results posted.
Among the 122 studies in Hypertension by Boehringer Ingelheim, this one is the 68th largest by enrollment of the 74 interventional ones that give a count, is one of 8 that started in 2010, is one of 43 in phase 3, and was the 58th registered.
Boehringer Ingelheim’s Hypertension studies by the year they started, since 1995.
None of the studies under way reaches primary completion within a year.
Among the 99 studies testing telmisartan in Hypertension, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Boehringer Ingelheim’s 122 in Hypertension:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The primary objectives of this trial is to evaluate the changes from baseline (Visit 2) in the 24-hour Ambulatory Blood Pressure Monitoring mean (relative to dose time) for diastolic blood pressure and systolic blood pressure after 8 weeks of treatment with Telmisartan 80mg/Amlodipine 5mg in patients with moderate to severe hypertension
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients will be given placebo for 2 weeks for wash-out, then qualified patients will be administered Telmisartan 80mg/Amlodipine 5mg for 8 weeks.
Drug: telmisartan+amlodipine fixed dose combination
Drug pages: Telmisartan · Amlodipine
after 2 weeks placebo wash-out, patients will be administered Telmisartan 80mg/Amlodipine 5mg for 8 weeks.
DBP and SBP Change From Baseline in Mean 24-hour Ambulatory Blood Pressure Monitoring (ABPM) Mean
ABPM measurements were taken every 20 minutes throughout the day and night by the validated SpaceLabs Model 90217 monitor.
Time frame: 8 weeks
Change From Baseline in ABPM Hourly Mean DBP and SBP, Starting 1 Hour After Dosing
Changes from baseline in DBP and SBP hourly means over the 24-hour dosing interval as measured by ABPM after 8 weeks of treatment with T80/A5
Time frame: 8 weeks
Trough to Peak (T/P) Ratio for DBP and SBP After 8 Weeks of Treatment
Calculated on the basis of changes in hourly means from baseline. Trough is defined as the mean of the last three hours of the 24-hour dosing interval. Peak is the greatest reduction in hourly means in hours 2 to 8 after dosing. All measurements are using ABPM.
Time frame: 8 weeks
Change From Baseline to End of Study in DBP and SBP
Manually measured in-clinic DBP and SBP
Time frame: 8 weeks
ABPM Hourly Mean DBP and SBP at Baseline and the End of the Study, Starting 1 Hour After Dosing
DBP and SBP hourly means over the 24-hour dosing interval as measured by ABPM at baseline and after 8 weeks of treatment
Time frame: 0 and 8 weeks
Treatment Emergent Adverse Events
Electrocardiogram, laboratory parameters and physical examinations were performed and any abnormal findings were recorded within the adverse events
Time frame: 8 weeks
Change From Baseline to End of Study in In-clinic Pulse Rate
Time frame: 8 weeks
| Milestone | T80/A5 |
|---|---|
| Started | 27 |
| Completed | 26 |
| Not completed | 1 |
| Withdrew: Adverse event | 1 |
ABPM measurements were taken every 20 minutes throughout the day and night by the validated SpaceLabs Model 90217 monitor.
| mmHg | T80/A5 |
|---|---|
| DBP change from baseline | -12.76 ± 7.42 |
| SBP change from baseline | -23.82 ± 14.54 |
Changes from baseline in DBP and SBP hourly means over the 24-hour dosing interval as measured by ABPM after 8 weeks of treatment with T80/A5
| mmHg | T80/A5 |
|---|---|
| DBP Change from baseline after 1 hour | -12.5 ± 10.7 |
| DBP Change from baseline after 2 hours | -14.7 ± 14.2 |
| DBP Change from baseline after 3 hours | -13.7 ± 13.9 |
| DBP Change from baseline after 4 hours | -11.7 ± 10.9 |
| DBP Change from baseline after 5 hours | -9.9 ± 15.6 |
| DBP Change from baseline after 6 hours | -11.7 ± 13.4 |
| DBP Change from baseline after 7 hours | -15.9 ± 12.3 |
| DBP Change from baseline after 8 hours | -14.8 ± 9.2 |
| DBP Change from baseline after 9 hours | -13.7 ± 11.1 |
| DBP Change from baseline after 10 hours | -12.9 ± 13.3 |
| DBP Change from baseline after 11 hours | -13.6 ± 13.0 |
| DBP Change from baseline after 12 hours | -13.1 ± 12.5 |
| DBP Change from baseline after 13 hours | -13.2 ± 12.4 |
| DBP Change from baseline after 14 hours | -11.9 ± 14.8 |
| DBP Change from baseline after 15 hours | -11.5 ± 12.8 |
| DBP Change from baseline after 16 hours | -11.8 ± 18.3 |
| DBP Change from baseline after 17 hours | -12.6 ± 14.0 |
| DBP Change from baseline after 18 hours | -13.1 ± 12.2 |
| DBP Change from baseline after 19 hours | -11.8 ± 10.6 |
| DBP Change from baseline after 20 hours | -10.7 ± 13.2 |
| DBP Change from baseline after 21 hours | -9.0 ± 13.4 |
| DBP Change from baseline after 22 hours | -13.8 ± 15.8 |
| DBP Change from baseline after 23 hours | -13.9 ± 9.8 |
| DBP Change from baseline after 24 hour | -14.8 ± 12.1 |
| SBP Change from baseline after 1 hour | -25.0 ± 21.3 |
| SBP Change from baseline after 2 hours | -26.2 ± 22.7 |
| SBP Change from baseline after 3 hours | -30.1 ± 26.3 |
| SBP Change from baseline after 4 hours | -21.9 ± 20.3 |
| SBP Change from baseline after 5 hours | -23.9 ± 19.7 |
| SBP Change from baseline after 6 hours | -23.9 ± 22.6 |
| SBP Change from baseline after 7 hours | -29.2 ± 18.8 |
| SBP Change from baseline after 8 hours | -27.6 ± 18.0 |
| SBP Change from baseline after 9 hours | -27.7 ± 21.1 |
| SBP Change from baseline after 10 hours | -25.8 ± 20.2 |
| SBP Change from baseline after 11 hours | -22.8 ± 20.4 |
| SBP Change from baseline after 12 hours | -23.4 ± 19.2 |
| SBP Change from baseline after 13 hours | -22.4 ± 19.5 |
| SBP Change from baseline after 14 hours | -22.1 ± 20.8 |
| SBP Change from baseline after 15 hours | -22.9 ± 19.4 |
| SBP Change from baseline after 16 hours | -24.4 ± 22.5 |
| SBP Change from baseline after 17 hours | -23.3 ± 19.9 |
| SBP Change from baseline after 18 hours | -21.7 ± 22.2 |
| SBP Change from baseline after 19 hours | -21.2 ± 16.8 |
| SBP Change from baseline after 20 hours | -20.5 ± 21.2 |
| SBP Change from baseline after 21 hours | -17.0 ± 24.6 |
| SBP Change from baseline after 22 hours | -19.2 ± 25.8 |
| SBP Change from baseline after 23 hours | -24.6 ± 15.6 |
| SBP Change from baseline after 24 hour | -25.1 ± 16.9 |
Calculated on the basis of changes in hourly means from baseline. Trough is defined as the mean of the last three hours of the 24-hour dosing interval. Peak is the greatest reduction in hourly means in hours 2 to 8 after dosing. All measurements are using ABPM.
| Ratio | T80/A5 |
|---|---|
| DBP T/P ratio (N=23) | 1.13 ± -14.9, 15.8 |
| SBP T/P ratio (N=25) | 0.98 ± -7.6, 14.0 |
Manually measured in-clinic DBP and SBP
| mmHg | T80/A5 |
|---|---|
| DBP: Change from baseline to 2 weeks | -9.67 ± 7.14 |
| DBP: Change from baseline to 4 weeks | -13.49 ± 7.22 |
| DBP: Change from baseline to 8 weeks | -13.73 ± 6.58 |
| SBP: Change from baseline to 2 weeks | -11.04 ± 8.99 |
| SBP: Change from baseline to 4 weeks | -17.95 ± 10.53 |
| SBP: Change from baseline to 8 weeks | -19.80 ± 9.96 |
DBP and SBP hourly means over the 24-hour dosing interval as measured by ABPM at baseline and after 8 weeks of treatment
| mmHg | T80/A5 |
|---|---|
| DBP after 1 hour at baseline | 101.6 ± 10.2 |
| DBP after 2 hours at baseline | 101.7 ± 13.2 |
| DBP after 3 hours at baseline | 100.0 ± 11.1 |
| DBP after 4 hours at baseline | 97.9 ± 9.5 |
| DBP after 5 hours at baseline | 95.3 ± 11.3 |
| DBP after 6 hours at baseline | 96.5 ± 11.6 |
| DBP after 7 hours at baseline | 97.0 ± 12.6 |
| DBP after 8 hours at baseline | 100.6 ± 9.8 |
| DBP after 9 hours at baseline | 102.7 ± 10.3 |
| DBP after 10 hours at baseline | 100.4 ± 11.2 |
| DBP after 11 hours at baseline | 97.9 ± 11.8 |
| DBP after 12 hours at baseline | 95.9 ± 11.0 |
| DBP after 13 hours at baseline | 93.6 ± 11.8 |
| DBP after 14 hours at baseline | 92.0 ± 11.5 |
| DBP after 15 hours at baseline | 89.4 ± 11.9 |
| DBP after 16 hours at baseline | 89.1 ± 16.8 |
| DBP after 17 hours at baseline | 88.0 ± 10.4 |
| DBP after 18 hours at baseline | 88.8 ± 11.6 |
| DBP after 19 hours at baseline | 88.4 ± 10.3 |
| DBP after 20 hours at baseline | 90.3 ± 12.9 |
| DBP after 21 hours at baseline | 91.4 ± 10.4 |
| DBP after 22 hours at baseline | 97.6 ± 14.2 |
| DBP after 23 hours at baseline | 101.0 ± 10.0 |
| DBP after 24 hours at baseline | 101.8 ± 9.3 |
| DBP after 1 hour at the end of the study | 89.1 ± 8.5 |
| DBP after 2 hours at the end of the study | 87.1 ± 11.0 |
| DBP after 3 hours at the end of the study | 86.3 ± 11.1 |
| DBP after 4 hours at the end of the study | 86.2 ± 10.1 |
| DBP after 5 hours at the end of the study | 85.3 ± 10.2 |
| DBP after 6 hours at the end of the study | 84.8 ± 11.4 |
| DBP after 7 hours at the end of the study | 81.1 ± 12.8 |
| DBP after 8 hours at the end of the study | 85.8 ± 7.5 |
| DBP after 9 hours at the end of the study | 88.9 ± 9.7 |
| DBP after 10 hours at the end of the study | 87.5 ± 10.5 |
| DBP after 11 hours at the end of the study | 84.3 ± 9.6 |
| DBP after 12 hours at the end of the study | 82.8 ± 9.1 |
| DBP after 13 hours at the end of the study | 80.4 ± 10.2 |
| DBP after 14 hours at the end of the study | 80.1 ± 13.6 |
| DBP after 15 hours at the end of the study | 77.9 ± 11.4 |
| DBP after 16 hours at the end of the study | 77.3 ± 8.9 |
| DBP after 17 hours at the end of the study | 75.5 ± 11.2 |
| DBP after 18 hours at the end of the study | 75.7 ± 11.5 |
| DBP after 19 hours at the end of the study | 76.6 ± 9.7 |
| DBP after 20 hours at the end of the study | 79.6 ± 10.4 |
| DBP after 21 hours at the end of the study | 82.4 ± 10.5 |
| DBP after 22 hours at the end of the study | 83.8 ± 12.5 |
| DBP after 23 hours at the end of the study | 87.2 ± 10.4 |
| DBP after 24 hours at the end of the study | 87.0 ± 12.4 |
| SBP after 1 hour at baseline | 157.9 ± 17.9 |
| SBP after 2 hours at baseline | 156.5 ± 20.1 |
| SBP after 3 hours at baseline | 158.4 ± 21.4 |
| SBP after 4 hours at baseline | 152.6 ± 15.9 |
| SBP after 5 hours at baseline | 152.1 ± 21.1 |
| SBP after 6 hours at baseline | 152.6 ± 24.6 |
| SBP after 7 hours at baseline | 154.6 ± 23.3 |
| SBP after 8 hours at baseline | 157.3 ± 19.6 |
| SBP after 9 hours at baseline | 161.0 ± 18.6 |
| SBP after 10 hours at baseline | 157.6 ± 20.2 |
| SBP after 11 hours at baseline | 153.3 ± 21.8 |
| SBP after 12 hours at baseline | 150.0 ± 20.8 |
| SBP after 13 hours at baseline | 145.8 ± 22.2 |
| SBP after 14 hours at baseline | 146.3 ± 22.7 |
| SBP after 15 hours at baseline | 141.9 ± 23.9 |
| SBP after 16 hours at baseline | 142.2 ± 26.2 |
| SBP after 17 hours at baseline | 139.6 ± 19.1 |
| SBP after 18 hours at baseline | 137.8 ± 22.9 |
| SBP after 19 hours at baseline | 139.2 ± 20.5 |
| SBP after 20 hours at baseline | 142.2 ± 21.6 |
| SBP after 21 hours at baseline | 143.6 ± 20.6 |
| SBP after 22 hours at baseline | 148.5 ± 22.2 |
| SBP after 23 hours at baseline | 156.6 ± 18.9 |
| SBP after 24 hours at baseline | 158.2 ± 16.6 |
| SBP after 1 hour at the end of the study | 132.8 ± 15.0 |
| SBP after 2 hours at the end of the study | 130.2 ± 15.3 |
| SBP after 3 hours at the end of the study | 128.3 ± 17.9 |
| SBP after 4 hours at the end of the study | 130.6 ± 17.8 |
| SBP after 5 hours at the end of the study | 128.2 ± 19.1 |
| SBP after 6 hours at the end of the study | 128.8 ± 17.3 |
| SBP after 7 hours at the end of the study | 125.5 ± 19.4 |
| SBP after 8 hours at the end of the study | 129.7 ± 15.5 |
| SBP after 9 hours at the end of the study | 133.2 ± 16.8 |
| SBP after 10 hours at the end of the study | 131.7 ± 17.3 |
| SBP after 11 hours at the end of the study | 130.5 ± 17.8 |
| SBP after 12 hours at the end of the study | 126.6 ± 15.9 |
| SBP after 13 hours at the end of the study | 123.5 ± 15.8 |
| SBP after 14 hours at the end of the study | 124.2 ± 19.9 |
| SBP after 15 hours at the end of the study | 119.1 ± 14.6 |
| SBP after 16 hours at the end of the study | 117.8 ± 14.6 |
| SBP after 17 hours at the end of the study | 116.4 ± 16.0 |
| SBP after 18 hours at the end of the study | 116.1 ± 18.4 |
| SBP after 19 hours at the end of the study | 118.0 ± 17.8 |
| SBP after 20 hours at the end of the study | 121.7 ± 19.0 |
| SBP after 21 hours at the end of the study | 126.6 ± 18.3 |
| SBP after 22 hours at the end of the study | 129.3 ± 21.5 |
| SBP after 23 hours at the end of the study | 132.0 ± 16.6 |
| SBP after 24 hours at the end of the study | 133.1 ± 20.2 |
Electrocardiogram, laboratory parameters and physical examinations were performed and any abnormal findings were recorded within the adverse events
| Participants | T80/A5 |
|---|---|
| Patients with any AEs | 4 |
| Patients with severe AEs | 0 |
| Patients with drug-related AEs | 1 |
| Patients with AEs related to laboratory changes | 0 |
| beats per minute (bpm) | T80/A5 |
|---|---|
| Change From Baseline to End of Study in In-clinic Pulse Rate | 2.37 ± 5.95 |
Collected over 8 weeks. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| T80/A5 | — | 0/27 (0%) | 0/27 (0%) |
| Age, Continuous(Years) | T80/A5 |
|---|---|
| Mean | 52.0 ± 8.7 |
| Sex: Female, Male(Participants) | T80/A5 |
|---|---|
| Female | 8 |
| Male | 17 |
| Mean 24-hour mean Diastolic blood pressure (DBP)(mmHg) | T80/A5 |
|---|---|
| Mean | 95.79 ± 7.74 |
| Mean 24-hour mean Systolic blood pressure (SBP)(mmHg) | T80/A5 |
|---|---|
| Mean | 150.24 ± 17.30 |
The record gives a start of Nov 2010 and a primary completion of Jul 2011. It does not say whether these dates are actual or estimated.
Results were first posted in Aug 2012, 1 year 1 month after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2013. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Telmisartan · Amlodipine